Stock CABA CABALETTA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq
Other stock markets
 02:00:01 07/05/2024 am IST 		5-day change 1st Jan Change
12.86 USD +3.79% Intraday chart for Cabaletta Bio, Inc. +22.71% -43.35%
22/03 HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating MT
21/03 Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Cabaletta Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c271b1f8ad426d9173b4a9b.drIChVRbaP0RWu-h2i5mndGuCL2-BbBnfuZy_UuH80M.G4FQ6S4OXbh9LqvXvko3_4HeaY7xVfkBG9MYmnPF3gJO-EDtARlblzwCnA~a695f054260fbe893d7b5f8e93f43f25

Analyst Recommendations on Cabaletta Bio, Inc.

HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating MT
Jefferies Initiates Cabaletta Bio with Buy Rating, $36 Price Target MT
Morgan Stanley Cuts Price Target on Cabaletta Bio to $25 From $28 as FDA Probes T-Cell Malignancies in CAR-T Cell Therapy, Keeps Overweight Rating MT
Cantor Fitzgerald Adjusts Price Target on Cabaletta Bio to $50 From $40, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Cabaletta Bio to $25 From $17, Keeps Buy Rating MT
Cantor Fitzgerald Initiates Cabaletta Bio With Overweight Rating, Price Target is $40 MT
Stifel Starts Cabaletta Bio With Buy Rating, Price Target is $31 MT
Wells Fargo Raises Price Target on Cabaletta Bio to $39 From $14, Keeps Overweight Rating MT
Citigroup Starts Cabaletta Bio at Buy With $22 Price Target MT
HC Wainwright Adjusts Price Target on Cabaletta Bio to $17 From $15, Maintains Buy Rating MT
Guggenheim Initiates Cabaletta Bio at Buy With $34 Price Target MT
HC Wainwright Adjusts Price Target on Cabaletta Bio to $15 From $11, Maintains Buy Rating MT
Morgan Stanley Upgrades Cabaletta Bio to Overweight From Equal Weight, $16 Price Target MT
Wells Fargo Boosts Price Target on Cabaletta Bio to $14 From $4, Keeps Overweight Rating MT
Chardan Trims Price Target on Cabaletta Bio to $12 From $13, Affirms Buy Rating MT
Wells Fargo Adjusts Cabaletta Bio's Price Target to $4 From $14, Maintains Overweight Rating MT
Morgan Stanley Downgrades Cabaletta Bio to Equalweight from Overweight, Adjusts Price Target to $3 from $15 MT
Chardan Research Adjusts Price Target on Cabaletta Bio to $13 From $17, Reiterates Buy Rating MT
Mizuho Securities Adjusts Cabaletta Bio's Price Target to $10 From $20, Reiterates Buy Rating MT
Evercore ISI Cuts Cabaletta Bio's Price Target to $15 From $20, Maintains Outperform Rating MT
Wells Fargo Raises Cabaletta Bio's Price Target to $16 From $17, Maintains Overweight Rating MT
Mizuho Securities Adjusts Cabaletta Bio's Price Target to $20 From $22, Reiterates Buy Rating MT
HC Wainwright Adjusts Cabaletta Bio's Price Target to $11 From $22, Keeps Buy Rating MT
Evercore ISI Lowers Price Target for Cabaletta Bio to $20 From $28, Maintains Outperform Rating MT
Morgan Stanley Lowers Price Target for Cabaletta Bio to $15 From $20, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
12.39 USD
Average target price
34.5 USD
Spread / Average Target
+178.45%
High Price Target
50 USD
Spread / Highest target
+303.55%
Low Price Target
25 USD
Spread / Lowest Target
+101.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cabaletta Bio, Inc.

HC Wainwright
Jefferies & Co.
Morgan Stanley
Cantor Fitzgerald
Stifel Nicolaus
Wells Fargo Securities
Citigroup
Guggenheim
Chardan Research
Mizuho Securities
Evercore ISI
Chardan

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CABA Stock
  4. Consensus Cabaletta Bio, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW